Ursodeoxycholic Acid for Treatment of Nonalcoholic Steatohepatitis: Results of a Randomized Trial

Hepatology

Volumn 39, Issue 3, 2004, Pages 770-778

  Lindor, Keith D ^a   Kowdley, Kris V ^b   Heathcote, E Jenny ^c   Harrison, M Edwyn ^d   Jorgensen, Roberta ^a   Angulo, Paul ^a   Lymp, James F ^a   Burgart, Lawrence ^a   Colin, Patrick ^e  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c TORONTO WESTERN HOSPITAL   (Canada)

^d MAYO CLINIC   (United States)

^e Axcan Pharma Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; LIVER ENZYME; PLACEBO; URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; BODY WEIGHT; CANCER; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; EAR DISEASE; ENDOCRINE DISEASE; ENZYME BLOOD LEVEL; EYE DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; GYNECOLOGIC DISEASE; HEMATOLOGIC DISEASE; HEPATITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY DISEASE; LIVER BIOPSY; LIVER DISEASE; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NONALCOHOLIC FATTY LIVER; NOSE DISEASE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RISK FACTOR; SEX DIFFERENCE; SKIN DISEASE; SYSTEMIC DISEASE; THROAT DISEASE; UROGENITAL TRACT DISEASE;

ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; CHOLAGOGUES AND CHOLERETICS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FATTY LIVER; FIBROSIS; HUMANS; LIVER; NECROSIS; URSODEOXYCHOLIC ACID;

EID: 1542515099     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20092     Document Type: Article

References (28)

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438.
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
3. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002;122:1649-1657.
4. Ruhl C, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the U.S. Gastroenterology 2003;124:71-79.
5. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, Cristanini G, et al. Prevalence of and risk factors for hepatic steatosis in northern Italy. Ann Intern Med 2000;132:112-117.
6. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988;27:142-149.
7. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. HEPATOLOGY 1990;30:1356-1362.
8. Matteoni CA, Younossi SM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
9. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carrucci P, Musso A, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-140.
10. Charlton M, Kasparova P, Weston S, Lindor K, Maor-Kendler Y, Wiesner RH, Rosen CB, et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 2001;7:608-614.
11. Angulo P, Lindor KD. Treatment of nonalcoholic fatty liver: present and emerging therapies. Semin Liver Dis 2001;21:81-88.
12. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001;358;893-894.
13. Caldwell SH, Hespenheide EE, Redlick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:519-525.
14. Neuschwander-Tetri BA, Brunt EM, Bacon BR, Sponseller C, Wehmeier KR. Histological improvement in NASH following reduction in insulin resistance with 48-week treatment with PPARγ agonist rosiglitazone [abstract]. HEPATOLOGY 2002;36:379A.
15. Abdelmalek M, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001;96:2711-2717.
16. Hasegawa T, Yoneda M, Makamura K, Makino I, Terano A. Plasma transforming growth factor-β1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001;15:1667-1672.
17. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid "mechanisms of action and clinical use in hepatobiliary disorders". J Hepatol 2001;35:134-146.
18. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, et al. Ursodeoxycholic acid or clofibrate in the treatment on non-alcoholic-induced steatohepatitis: a pilot study. HEPATOLOGY 1996;23:1464-1467.
19. Brunt EM, Janney G, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-2474.
20. Kobak GE, Deutsch G, Dahl R, Devereaux MW, Gumpricht E, Sokol RJ. Fat-laden hepatocytes are more prone to cellular necrosis than apoptosis when exposed to hydrophobic bile acids. Gastroenterology 2002;122:A642.
21. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE, et al. Reversal of obesity and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001;293:1673-1677.
22. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997;389:610-614.
23. Neuman M, Angulo P, Malkiewicz I, Jorgensen R, Shear N, Dickson ER, Haber J, et al. Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. J Gastroenterol Hepatol 2002;17:196-202.
24. Angulo P, Dickson ER, Therneau TM, Jorgensen RA, Smith C, DeSotel CK, Lange SM, et al. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol 1999;30:830-835.
25. Harnois D, Angulo P, Jorgensen RA, LaRusso NF, Lindor KD. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001;96:1558-1562.
26. Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001;121:900-907.
27. Colombo C, Crosignani A, Assaisso M, Battezzati PM, Podda M, Giunta A, Zimmer-Nechemias L, et al. Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: A dose-response study. HEPATOLOGY 1992;16:924-930.
28. Abdelmalek M, Ludwig J, Lindor KD. Two cases from the spectrum of nonalcoholic steatohepatitis. J Clin Gastroenterol 1995;20:127-130.